1. Home
  2. NCA vs AKBA Comparison

NCA vs AKBA Comparison

Compare NCA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Municipal Value Fund

NCA

Nuveen California Municipal Value Fund

HOLD

Current Price

$8.68

Market Cap

294.0M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.94

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCA
AKBA
Founded
1987
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
294.0M
343.4M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
NCA
AKBA
Price
$8.68
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
74.8K
8.6M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
3.92%
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.57
$0.81
52 Week High
$9.80
$3.19

Technical Indicators

Market Signals
Indicator
NCA
AKBA
Relative Strength Index (RSI) 29.48 46.76
Support Level N/A $0.84
Resistance Level $9.49 $0.96
Average True Range (ATR) 0.15 0.06
MACD -0.03 0.00
Stochastic Oscillator 2.27 37.19

Price Performance

Historical Comparison
NCA
AKBA

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: